TScan director granted 67,000 stock options

TScan Therapeutics director Katina Dorton received a grant of stock options covering 67,000 shares of Voting Common Stock.

Rhea-AI Filing Summary

TScan Therapeutics director Katina Dorton received a grant of stock options covering 67,000 shares of Voting Common Stock. The options have an exercise price of $0.9946 per share and expire on May 20, 2036.

The options vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders, as long as she continues in service. After this grant, she holds 67,000 options directly, and there were no reported share purchases or sales in this filing.

Insider Trade Summary

Grant/Award: 67,000 shares

Grant/Award 1 txn

Insider Dorton Katina

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	67,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 67,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

Key Figures

Option grant size: 67,000 options Exercise price: $0.9946 per share Expiration date: May 20, 2036 +2 more

5 metrics

Option grant size 67,000 options Stock Option (Right to Buy) granted on May 20, 2026

Exercise price $0.9946 per share Exercise price for granted stock options

Expiration date May 20, 2036 Option expiration for this grant

Post-transaction holdings 67,000 options Total options held directly after the grant

Vesting date trigger Earlier of May 20, 2027 or next annual meeting Full vesting condition subject to continued service

Key Terms

Stock Option (Right to Buy), Voting Common Stock, exercise price, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Voting Common Stock financial

"underlying_security_title: Voting Common Stock"

exercise price financial

"conversion_or_exercise_price: 0.9946"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to this option shall vest and become exercisable in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TScan Therapeutics (TCRX) report for Katina Dorton?

TScan Therapeutics reported that director Katina Dorton received a grant of stock options for 67,000 shares of Voting Common Stock. This is a compensation-related award rather than an open-market share purchase or sale, and no common shares were traded in this filing.

What is the exercise price and term of Katina Dorton’s new TScan (TCRX) stock options?

The granted stock options have an exercise price of $0.9946 per share and expire on May 20, 2036. This means she can choose to buy up to 67,000 shares at that price any time after vesting until the expiration date.

When do Katina Dorton’s TScan Therapeutics (TCRX) options vest and become exercisable?

The options vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of TScan’s stockholders. Vesting is conditioned on her continued service with the company through that vesting date, according to the footnote disclosure.

Did Katina Dorton buy or sell any TScan Therapeutics (TCRX) common shares in this Form 4?

No common share purchases or sales were reported. The Form 4 only shows a grant of stock options for 67,000 underlying Voting Common Stock shares, classified as a grant or award acquisition, with no open-market buying or selling activity disclosed in this filing.

How many TScan (TCRX) options does Katina Dorton hold after this reported grant?

Following the reported transaction, Katina Dorton holds 67,000 stock options directly. These options each relate to one share of Voting Common Stock and reflect her entire derivative position visible in this specific Form 4, with no additional derivative holdings listed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/22/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dorton Katina

(Last) (First) (Middle)

C/O TSCAN THERAPEUTICS, INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TScan Therapeutics, Inc. [ TCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.9946	05/20/2026		A		67,000		(1)	05/20/2036	Voting Common Stock	67,000	$0.00	67,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

	/s/ Zoran Zdraveski, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)